Dexamethasone Impact on Glioblastoma Management

Dexamethasone remains the cornerstone for alleviation of vasogenic oedema and intracranial pressure in patients with glioblastoma, offering rapid symptomatic relief and facilitation of surgical or radiotherapeutic interventions. However, its potent glucocorticoid-mediated immunosuppression has emerged as a double-edged sword: while reducing peritumoral swelling, it can impair lymphocyte activation, skew peripheral immune composition and attenuate the efficacy of emerging immunotherapies. Observational analyses have correlated higher dexamethasone dosing with shorter progression-free and overall survival, prompting a reassessment of dosing schedules and the exploration of steroid-sparing approaches. Mechanistic studies in ex vivo brain slice models and cell culture have further revealed context-dependent interactions between dexamethasone, microglial activity and chemokine signalling, suggesting that glucocorticoid effects on tumour outgrowth and dispersal are modulated by the local immune microenvironment. Taken together, these findings underline the necessity of balancing cerebral oedema control against potential detriments to treatment response, thereby informing refined clinical guidelines and the integration of targeted strategies to mitigate steroid-induced immunosuppression.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Dexamethasone Impact on Glioblastoma Management publication trend

The graph below shows the total number of articles in dexamethasone impact on glioblastoma management across all publications each year (not limited to Nature Index journals).

Technical terms

Glioblastoma: The most aggressive primary malignant brain tumour, characterised by diffuse infiltration and poor prognosis.

Dexamethasone: A synthetic glucocorticoid used to reduce cerebral oedema and intracranial pressure.

Corticosteroid: A class of steroid hormones that modulate inflammation and immune responses.

Oedema: Accumulation of fluid in brain tissue leading to swelling and raised intracranial pressure.

Immunosuppression: Reduction of immune system activity, which can compromise anti-tumour responses.

Progression-free survival (PFS): The length of time during and after treatment that a patient lives without tumour growth.

Overall survival (OS): The duration from diagnosis or treatment initiation until death from any cause.

Natural killer (NK) cells: A subset of lymphocytes that mediate innate immune cytotoxicity against tumour cells.

Memory B cells: Antigen-experienced B lymphocytes that contribute to long-term humoral immunity.

References

1. The immunological landscape of peripheral blood in glioblastoma patients and immunological consequences of age and dexamethasone treatment. Frontiers in Immunology (2024).
2. CXCR2-Blocking Has Context-Sensitive Effects on Rat Glioblastoma Cell Line Outgrowth (S635) in an Organotypic Rat Brain Slice Culture Depending on Microglia-Depletion (PLX5622) and Dexamethasone Treatment. International Journal of Molecular Sciences (2023).
3. Dexamethasone in Patients with Glioblastoma: A Systematic Review and Meta-Analysis. Cancers (2024).
4. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. Journal for ImmunoTherapy of Cancer (2018).
5. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Current Oncology (2014).